๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Pancreatic Cancer
Clinical trial register · China

Pancreatic Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 53 Beijing 25 Wuhan 15 Hangzhou 13 Nanjing 12
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fudan University14 Changhai Hospital9 Tianjin Medical University Cancer Institute and Hospital7 Ruijin Hospital7 Peking Union Medical College Hospital7
Site location
Shanghai53 Beijing25 Wuhan15 Hangzhou13 Nanjing12
All 38 locations
Target enrolment
to

Pancreatic Cancer trials in China

132 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Albumin-bound Paclitaxel (โ…ก)-Combined Regimens for Pancreatic Cancer
NCT07828756Pancreatic Cancer
DrugsAlbumin-Bound Paclitaxel·Capecitabine·Gemcitabine·Cisplatin
Tianjin Medical University Cancer Institute and Hospital
Phase 2
147
Tianjin
2026-09-30
Not yet open
An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors
NCT07806058Pancreatic Cancer
DrugsHRS-7172·HRS-4642·Adebrelimab
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
140
Shanghai
2026-09
Not yet open
Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer
NCT07814859Pancreatic Cancer
DrugsFamitinib·Retlirafusp alfa
The First Affiliated Hospital of Zhengzhou University
Phase 2
88
Zhengzhou
2026-08-31
Not yet open
A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation
NCT07784374Pancreatic Cancer
DrugsGFS202A·GFH276·Cetuximab
Genfleet Therapeutics (Shanghai) Inc.
Phase 2
120
Shanghai
2026-08-31
Not yet open
Baduanjin for Quality of Life in Pancreatic Cancer Chemotherapy
NCT07791550Pancreatic Neoplasms, Pancreatic Cancer, Drug-Related Side Effects and Adverse Reactions (MeSH Term)
Tianjin Medical University Cancer Institute and Hospital
Not applicable
96
Tianjin
2026-08-28
Not yet open
Five-Element Music Therapy for Psychological Distress in Pancreatic Cancer Chemotherapy
NCT07796906Pancreatic Neoplasms, Pancreatic Cancer, Anxiety, Depression and/or Anxiety Symptoms
Tianjin Medical University Cancer Institute and Hospital
Not applicable
320
Tianjin
2026-08-28
Not yet open
A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer
NCT07736612Pancreatic Cancer, RAS Mutations or Amplifications
DrugsHRS-2329·HS-20093·Nimotuzumab·Adebrelimab
Zhejiang University
Phase 1/2
80
Hangzhou
2026-08-15
Recruiting
YMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies
NCT07763301Liver Cancer, Pancreatic Cancer, Biliary Tract Cancer (BTC)
DrugYMN-136 vaccine
West China Hospital
Phase 1
9
Chengdu
2026-08-01
Not yet open
SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer
NCT07683221Pancreatic Cancer
DrugsSBRT·IBI310·Sintilimab
Shandong Cancer Hospital and Institute
Phase 2
47
Jinan
2026-07-15
Recruiting
An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer
NCT07589569Pancreatic Cancer
DrugHRS-7058
Shandong Suncadia Medicine Co., Ltd.
Phase 2
92
Nanjing, Tianjin
2026-06-04
Recruiting
A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer
NCT07707531Gastric Cancer, Pancreatic Cancer
Huashan Hospital
Phase EARLY_PHASE1
10
Shanghai
2026-06-01
Recruiting
Multicentric Database for KRAS Mutant Pancreatic Cancer
NCT07557849Pancreatic Cancer
Fudan University
Observational
1,000
Shanghai
2026-05-22
Recruiting
Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery
NCT07632118Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 3
288
Tianjin
2026-05-22
Recruiting
A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer
NCT07649928Pancreatic Cancer
Ruijin Hospital
Phase EARLY_PHASE1
24
Shanghai
2026-05-18
Not yet open
Chimeric Antigen Receptor Macrophages Targeting c-MET for Advanced Stage of Pancreatic Cancer Patients
NCT07553793Pancreatic Cancer, Advanced Stage Cancer
Peking Union Medical College Hospital
Phase 1
18
Beijing
2026-05-01
Not yet open
A Study of DCTY1102 Injection in Participants With Advanced Solid Tumors
NCT07014878Colorectal Cancer, Lung Cancer, Pancreatic Cancer
Beijing DCTY Biotech Co.,Ltd.
Phase 1
18
Shanghai
2026-05
Recruiting
Spatial Multi-omics and Intelligent Early Warning of Pancreatic Cancer Cachexia
NCT07670286Pancreatic Cancer, Cachexia; Cancer; Sarcopenia
Peking Union Medical College Hospital
Observational
500
Beijing
2026-04-24
Not yet open
Non-Invasive Detection of claudin18.2 in Pancreatic and Gastric/Gastroesophageal Junction Cancer by [68Ga]Ga-NODAGA-SNA014 PET Imaging
NCT07554742Pancreatic Cancer, Gastric Cancer, Gastroesophageal Junction Cancer
Ruijin Hospital
Observational
64
Shanghai
2026-04-15
Recruiting
Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
NCT07552467Pancreatic Cancer, Breast Cancer, Lung Cancer, Sarcoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
26
Wuhan
2026-04-01
Recruiting
KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
NCT07353645Colorectal Cancer, Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1/2
49
Nanjing
2026-03-23
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
DrugsCetuximab·Nab-paclitaxel·Gemcitabine
Revolution Medicines, Inc.
Phase 3
900
2026-03-09
Active, closed
Research of the Application of Pancreatic Cancer Screening Artificial Intelligence Model "PANDAPro"
NCT06643715Pancreatic Cancer
Zhejiang University
Not applicable
100,000
Hangzhou
2026-03-07
Not yet open
EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases
NCT07448376CTCs, Pancreatic Cancer, Liver Metastases, Relapse
Huazhong University of Science and Technology
Observational
20
Wuhan
2026-03-01
Recruiting
AI-Powered Precision Decision-Making for Pancreatic Diseases
NCT07439757Pancreatic Cancer, Diagnose Disease, IPMN, Pancreatic, Pancreatic Cystic Lesions
Changhai Hospital
Observational
2,000
Shanghai
2026-03-01
Not yet open
A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer
NCT07383922Pancreatic Cancer
DrugsFG-M108·Nab-paclitaxel·Gemcitabine
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Phase 3
524
Shanghai
2026-02-28
Recruiting
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
NCT07409272Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
DrugsLevofolinate·Setidegrasib·Liposomal Irinotecan·5-FU
Astellas Pharma Global Development, Inc.
Phase 3
614
Shanghai
2026-02-17
Recruiting
CAR-NK Cells (CL-NK-003) in Pancreatic Cancer
NCT07425483Pancreatic Cancer
Changhai Hospital
Phase 1
9
Shanghai
2026-02-12
Not yet open
IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer
NCT07415525Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma
DrugIBI343
Zhejiang University
Phase 2
40
Hangzhou
2026-02-01
Not yet open
Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes
NCT07272109Pancreatic Cancer
DrugsNab-paclitaxel·Gemcitabine
Fudan University
Phase 3
210
Shanghai
2026-01-01
Recruiting
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors
NCT07586813Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gastrointestinal Neoplasms, Pancreatic Cancer
DrugsAll-trans retinoic acid·Romiplostim N01
Peking University People's Hospital
Phase 2
220
Beijing
2025-12-22
Recruiting
A Study on a Predictive Model for Efficacy and Prognosis of Pancreatic Carcinoma Based on Multimodal Data
NCT07561814Pancreatic Cancer
Shanghai Zhongshan Hospital
Observational
1,030
Shanghai
2025-12-09
Not yet open
Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer
NCT06177522Pancreatic Cancer, Neoadjuvant Therapy
DrugsAlbumin-Bound Paclitaxel·Adebrelimab·Gemcitabine
Jinling Hospital, China
Phase 2
30
Nanjing
2025-11-30
Recruiting
Clinical Study of 177Lu-CTR-FAPI In the Treatment of Patients With Advanced, Metastatic Solid Tumors
NCT07229768Pancreatic Cancer
Yan Xing
Phase EARLY_PHASE1
4
Shanghai
2025-10-15
Active, closed
Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer
NCT07173387Pancreatic Cancer
Shandong Cancer Hospital and Institute
Phase 2
42
Jinan
2025-10-01
Not yet open
Clinical Application of PET Imaging Targeting GPA33 in Malignant Tumors
NCT07172503Colorectal Cancer, Gastric Cancer (GC), Pancreatic Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not applicable
56
Wuhan
2025-10-01
Recruiting
Preliminary Trial of SNA014 for Pancreatic Cancer
NCT07597772Pancreatic Cancer
Drug68Ga-NODAGA-SNA006
SmartNuclide Biopharma
Phase EARLY_PHASE1
12
Tianjin
2025-10-01
Recruiting
LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
NCT07312422Pancreatic Cancer, PD-L1, PD-1 Inhibitor, LDRT
DrugsFolfirinox·Pucotenlimab
Zhejiang Provincial People's Hospital
Phase 1/2
10
Hangzhou
2025-09-30
Recruiting
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
NCT07114315Pancreatic Cancer
DrugsAK130·Ivonescimab
Akeso
Phase 2
160
Shanghai, Tianjin
2025-09-19
Recruiting
A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer
NCT07079228Pancreatic Cancer
DrugsQLS31905·Nab-paclitaxel·Gemcitabine
Qilu Pharmaceutical Co., Ltd.
Phase 3
602
Beijing
2025-09-08
Recruiting
Clinical Application of PET Imaging Targeting CLDN18.2 in Malignant Tumors
NCT07301814Gastric Cancer, Pancreatic Cancer, Cholangiocarcinoma Cancer, Esophageal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
56
Wuhan
2025-09-01
Recruiting
HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
NCT07131514Pancreatic Cancer
DrugsHRS-4642·Adebrelimab
Ruijin Hospital
Phase 2
30
Shanghai
2025-08-25
Not yet open
XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic Cancer
NCT07114666Pancreatic Cancer
DrugXH001
Peking Union Medical College Hospital
Not applicable
12
Beijing
2025-08-18
Recruiting
Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer
NCT07117045Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, High-grade Pancreatic Intraepithelial Neoplasia, PDAC - Pancreatic Ductal Adenocarcinoma
Changhai Hospital
Observational
400,000
Shanghai, Jiaxing, Ningbo
2025-08-15
Recruiting
A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
NCT07066098Pancreatic Cancer
DrugIBI343
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
201
Shanghai
2025-08-04
Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
DrugMRG007
ArriVent BioPharma, Inc.
Phase 1
572
Beijing, Chongqing, Zhejiang, Heilongjiang, Zhengzhou, Wuhan, Changsha, Shandong
2025-07-25
Recruiting
PGHD-AI Intelligent Model for the Nutritional Assessment and Intervention of Patients After Radical Surgery for Pancreatic Cancer.
NCT07167264Pancreatic Cancer
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
200
Shanghai
2025-07-16
Recruiting
Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
NCT07823049Pancreatic Cancer
DrugXNW28012
Evopoint Biosciences Inc.
Phase 3
226
Shanghai, Beijing, Binzhou, Changsha, Changzhou, Chengdu, Chongqing, Fuyang
2025-07-08
Not yet open
Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis
NCT06779318Pancreatic Cancer, Postoperative Adjuvant Therapy, Maintenance Therapy
DrugTislelizumab
The First Affiliated Hospital with Nanjing Medical University
Phase 4
464
Nanjing
2025-07
Recruiting
An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer
NCT06938282Pancreatic Cancer
DrugHRS-4642
Shanghai Zhongshan Hospital
Phase 2
60
Shanghai
2025-06-23
Recruiting
A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
NCT06953999Pancreatic Cancer
Akeso
Phase 3
999
Harbin, Shanghai, Hangzhou
2025-06-11
Recruiting
Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer
NCT07066995Pancreatic Cancer, Pancreatic Carcinoma, Pancreatic Cancer Non-resectable, Pancreatic Cancer Stage IV
Essen Biotech
Phase 1/2
60
Beijing
2025-04-29
Recruiting
A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)
NCT06962267Pancreatic Cancer
DrugTQB2916
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
50
Beijing
2025-04-18
Recruiting
18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis
NCT06937112Lung Cancers, Pancreatic Cancer, Neuroendocrine Tumors, Thyroid Cancer
Nanjing First Hospital, Nanjing Medical University
Observational
20
Nanjing
2025-04-10
Recruiting
CAR-NK Cells (CL-NK-001) in Pancreatic Cancer
NCT06816823Pancreatic Cancer
Changhai Hospital
Phase 1
30
Shanghai
2025-04-07
Recruiting
A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
NCT06944106Pancreatic Cancer
DrugIvonescimab
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2025-03-28
Recruiting
A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation
NCT06898385Pancreatic Cancer
DrugsFludarabine·Cyclophosphamide
Sun Yat-sen University
Phase 1
9
Guangzhou
2025-03-27
Recruiting
Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors๏ผšA Prospective Exploratory Study
NCT07542002Pancreatic Cancer
Ningbo Medical Center Lihuili Hospital
Phase 2
37
Ningbo
2025-03-25
Recruiting
A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer
NCT06758544Pancreatic Cancer
DrugOncolytic virus VRT106
Guangdong Provincial People's Hospital
Phase 1/2
18
Guangzhou
2025-03-17
Not yet open
A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer
NCT06866977Pancreatic Cancer
DrugOncolytic virus VRT106
Xiangya Hospital of Central South University
Phase 1/2
10
Changsha
2025-03-12
Recruiting
The Characteristics of Oral Microbiota in Chronic Pancreatitis and Autoimmune Pancreatitis
NCT07015580Oral Microbiota, Pancreatitis, Pancreatic Cancer
Ruijin Hospital
Observational
360
Shanghai
2025-02-18
Recruiting
A Study of GC203 TIL in PDCA (RJ)
NCT06828328Pancreatic Cancer, Pancratic Ductal Adenocarcinoma, Treatment Side Effects, Tumor Infiltrating Lymphocytes
DrugEngineering Tumor Infiltrating Lymphocytes
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1
10
Shanghai
2025-02-10
Recruiting
Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)
NCT06844422Pancreatic Cancer
DrugIvonescimab
Shandong Cancer Hospital and Institute
Phase 1/2
37
Jinan
2025-02-08
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Hefei, Beijing, Guangzhou, Wuhan, Harbin, Changsha, Chengdu, Hangzhou
2025-01-29
Recruiting
Pancreatic Cancer and Diabetes Mellitus
NCT06585072Pancreatic Cancer, Surgery, Diabetes Mellitus
Shanghai Changzheng Hospital
Observational
150
Shanghai
2025-01-03
Not yet open
Validation of Joint-AI in Diagnosing Pancreatic Solid Lesions
NCT06753318Pancreatic Cancer, Pancreatitis, Pancreatic Neuroendocine Neoplasms (pNETs), Autoimmune Pancreatitis
Huazhong University of Science and Technology
Not applicable
716
Wuhan
2025-01
Recruiting
HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
NCT06587061Pancreatic Cancer
DrugHRS-4642
Ruijin Hospital
Phase 2
30
Shanghai
2024-12-03
Recruiting
Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer
NCT06601283Pancreatic Cancer
Fudan University
Phase 2/3
50
Shanghai
2024-11-22
Recruiting
Vitamin C Plus Cordyceps to Quality of Life in Patients With Terminal Stage Pancreatic Cancer
NCT06598033Pancreatic Cancer
Fudan University
Phase 2/3
50
Shanghai
2024-11-22
Recruiting
NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor
NCT06134960Gastric Cancer, Pancreatic Cancer, Solid Tumor
Peking University
Phase 1
12
Beijing
2024-11-16
Recruiting
CtDNA-guided Maintenance Therapy in Pancreatic Cancer
NCT07054879Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
70
Nanjing
2024-11-01
Not yet open
Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)
NCT06621095Pancreatic Cancer, First-line, Metastatic Pancreatic Cancer
DrugsBenmelstobart·Anlotinib·Nab-paclitaxel·Gemcitabine
RenJi Hospital
Phase 2
104
Shanghai
2024-10-30
Active, closed
Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer
NCT06766019Pancreatic Cancer
DrugAdebrelimab
The First Affiliated Hospital with Nanjing Medical University
Phase 2
47
Nanjing
2024-10-16
Active, closed
MRD in PAAD Adjuvant Therapy
NCT06867146The Role of Molecular Residual Disease in the Treatment Strategy and Prognosis Prediction of Pancreatic Cancer Patients Undergoing Adjuvant Therapy, Molecular Residual Disease, Pancreatic Cancer, Adjuvant Therapy
Peking Union Medical College Hospital
Not applicable
60
Beijing
2024-10-15
Recruiting
Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer
NCT06547736Pancreatic Cancer
DrugsSHR-A1904·HRS-4642·SHR-A2102·Trastuzumab Rezetecan
Fudan University
Phase 2
160
Shanghai
2024-10-14
Recruiting
Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors
NCT06843629Ovarian Cancer, Lung Adenocarcinoma, Pancreatic Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
100
Wuhan
2024-10-01
Recruiting
Profiling the Intratumoral Microbiome of Pancreatic Ductal Adenocarcinoma Based on EUS-FNB Tissue Samples and Exploring Its Impact on Tumor Diagnosis and Prognosis.
NCT06655233Pancreatic Cancer, EUS-FNB, Intratumoral Microbiota, Diagnosis
The Third Xiangya Hospital of Central South University
Observational
50
Hunan
2024-10-01
Recruiting
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.
NCT06601010Pancreatic Cancer
Ruijin Hospital
Observational
30
Shanghai
2024-09-24
Recruiting
Irinotecan Liposome in Combination With Capecitabine
NCT06578052Pancreatic Cancer
Junjie Hang
Not applicable
20
Shenzhen
2024-08-28
Not yet open
Research of the Application of Artificial Intelligence Model "PANDA"
NCT06528223Pancreatic Cancer
Zhejiang University
Not applicable
200,000
Hangzhou
2024-08-15
Recruiting
Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC)
NCT06427447Pancreatic Cancer
Changhai Hospital
Phase 3
770
Shanghai
2024-08-06
Recruiting
AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort
NCT06638866Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraepithelial Neoplasias, Intraductal Papillary Mucinous Neoplasm
Changhai Hospital
Observational
5,000
Shanghai, Jiaxing, Ningbo
2024-08-03
Recruiting
Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer
NCT06435260Pancreatic Cancer
DrugCamrelizumab
Hebei Medical University Fourth Hospital
Phase 2
30
Shijiazhuang
2024-08-01
Recruiting
A New Strategy for Preoperative Drainage of Resectable Pancreatic Head Cancer Combined Severe Obstructive Jaundice
NCT06541340Pancreatic Cancer, Obstructive Jaundice
Ruijin Hospital
Not applicable
360
Shanghai
2024-08-01
Recruiting
Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
NCT06821048Colorectal Cancer, Stomach Cancer, Pancreatic Cancer, Metastatic Cancer
Weijia Fang, MD
Phase 1
18
Hangzhou
2024-07-24
Recruiting
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
NCT06500052Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer
DrugBL-M17D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
20
Guangzhou
2024-07-24
Recruiting
Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer
NCT06491472Pancreatic Cancer
DrugsIvonescimab·Nab-paclitaxel·Gemcitabine
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
36
Wuhan
2024-07-15
Active, closed
First-line Regimen With QL1706 Plus Chemo ยฑ Bev in PDAC Patients
NCT06313970Pancreatic Cancer
DrugsIparomlimab and Tuvonralimab·Nab-paclitaxel·Gemcitabine·Bevacizumab
Fudan University
Phase 2
58
Shanghai
2024-06-20
Recruiting
Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
NCT06427239Pancreatic Cancer
DrugsHRS-4642·SHR-8068·Adebrelimab·Bevacizumab
Fudan University
Phase 1/2
130
Shanghai
2024-06-17
Recruiting
PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients
NCT06359275Pancreatic Cancer
DrugsPD-1·Nab-paclitaxel·Gemcitabine
Fudan University
Phase 2
81
Shanhai
2024-06-01
Not yet open
Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer
NCT06361030Pancreatic Cancer, Pancreatic Cancer Non-resectable, Pancreatic Ductal Adenocarcinoma, PDAC
DrugsSurufatinib·Nab-paclitaxel·Gemcitabine
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
40
Wuhan
2024-06-01
Recruiting
A Study of JMT203 in Patients With Cancer Cachexia
NCT06868849Non Small Cell Lung Cancer, Pancreatic Cancer, Cancer Cachexia, Colorectal Cancer Cachexia
Shanghai JMT-Bio Inc.
Phase 1/2
307
Zhejiang
2024-05-15
Recruiting
Central-boost Ablative Radiation Therapy for Solid Tumors (CBART)
NCT06427460Pancreatic Cancer
Changhai Hospital
Phase 2
67
Shanghai
2024-05-12
Not yet open
Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
NCT06409429Pancreatic Cancer
DrugNimotuzumab
Tianjin Medical University Cancer Institute and Hospital
Phase 2/3
146
Tianjin
2024-05-01
Not yet open
Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC
NCT06346808Pancreatic Cancer
Sichuan University
Phase 1
20
Chengdu
2024-05-01
Not yet open
Newly Emerging Immunotherapy for Pancreatic Cancer Treatment
NCT06370754Pancreatic Cancer
DrugsJS015·JS007·JS004·Irinotecan liposome
Fudan University
Phase 1/2
117
Shanghai
2024-04-30
Recruiting
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
NCT06403735Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
Qilu Pharmaceutical Co., Ltd.
Phase 1
250
Guangzhou, Harbin, Nanchang, Shanghai, Kunming
2024-04-25
Recruiting
Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients
NCT06375473Pancreatic Cancer
DrugIrinotecan liposome II combination therapy
Peking Union Medical College Hospital
Observational
3,000
Hefei, Beijing, Nanning, Zhengzhou, Henan, Ningbo, Shanghai, Wuhan
2024-04-19
Recruiting
Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer
NCT06361316Pancreatic Cancer, Adjuvant Therapy
DrugIrinotecan liposome
Kuirong Jiang
Not applicable
53
Nanjing
2024-04-08
Recruiting
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy
NCT06249321Pancreatic Cancer, Radiotherapy
DrugsIMRT·MFOLFIRINOX
Fudan University
Phase 2
30
Shanghai
2024-04-01
Recruiting
Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer
NCT06344156Pancreatic Cancer, Adjuvant Therapy
DrugNeoantigen vaccine
Sichuan University
Phase 1
43
Chengdu
2024-04-01
Rows per page Showing 1–100 of 132
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/condition/pancreatic-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 132 of those studies listing the condition Pancreatic Cancer.

How many Pancreatic Cancer trials are recruiting in China?

91 of the 132 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 31 have not yet opened recruitment, 10 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Pancreatic Cancer), 132 studies
PhaseStudiesRecruitingShare
Phase 2352226.5%
Observational232117.4%
Phase 1/2181113.6%
Not applicable17812.9%
Phase 1151211.4%
Phase 31188.3%
Phase EARLY_PHASE1765.3%
Phase 2/3322.3%
Phase 4312.3%

Most active sponsors

Lead sponsors with the most studies (Pancreatic Cancer)
Lead sponsorStudiesRecruiting
Fudan University149
Changhai Hospital99
Peking Union Medical College Hospital74
Ruijin Hospital76
Tianjin Medical University Cancer Institute and Hospital73
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology64
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School44
Zhejiang University40
Akeso33
Shandong Cancer Hospital and Institute31
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.